Publicaciones en las que colabora con Isabel Lastres Becker (28)

2022

  1. New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

    Biomolecules, Vol. 12, Núm. 9

2021

  1. Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration

    Acta Neuropathologica Communications, Vol. 9, Núm. 1

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  3. Molecular alterations in sporadic and sod1-als immortalized lymphocytes: Towards a personalized therapy

    International Journal of Molecular Sciences, Vol. 22, Núm. 6, pp. 1-17

2013

  1. Nrf2 participates in depressive disorders through an anti-inflammatory mechanism

    Psychoneuroendocrinology, Vol. 38, Núm. 10, pp. 2010-2022

2010

  1. A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice

    PLoS ONE, Vol. 5, Núm. 7, pp. 1-15

2009

  1. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease

    GLIA, Vol. 57, Núm. 11, pp. 1154-1167

2006

  1. An overview of Parkinson's disease and the cannabinoid system and possible benefits of cannabinoid-based treatments

    Current Medicinal Chemistry, Vol. 13, Núm. 30, pp. 3705-3718

2005

  1. Cannabinoid CB1 receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice

    Brain Research, Vol. 1046, Núm. 1-2, pp. 195-206

  2. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease

    Neurobiology of Disease, Vol. 19, Núm. 1-2, pp. 96-107

2004

  1. Involvement of the endocannabinoid system in motor disorders

    Current Medicinal Chemistry - Central Nervous System Agents, Vol. 4, Núm. 3, pp. 175-182

  2. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: In vivo and in vitro evidence

    Brain Research, Vol. 1007, Núm. 1-2, pp. 152-159

  3. Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo

    NeuroReport, Vol. 15, Núm. 15, pp. 2375-2379

2003

  1. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease

    Journal of Neurochemistry, Vol. 84, Núm. 5, pp. 1097-1109

  2. Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate

    NeuroReport, Vol. 14, Núm. 6, pp. 813-816

  3. Implicación del sistema cannabinoide endógeno en enfermedades neurodegenerativas extrapiramidales

    Implicación del sistema cannabinoide endógeno en enfermedades neurodegenerativas extrapiramidales

  4. The endocannabinoid system and Huntington's disease.

    Current drug targets. CNS and neurological disorders, Vol. 2, Núm. 5, pp. 335-347

2002

  1. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease

    Synapse, Vol. 44, Núm. 1, pp. 23-35

  2. Endocannabinoids and basal ganglia functionality

    Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 66, Núm. 2-3, pp. 257-267

  3. Loss of cannabinoid CB1 receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease

    Neurotoxicity Research, Vol. 4, Núm. 7-8, pp. 601-608